A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer
Jean‐Charles Soria, Alex A. Adjei, Rastilav Bahleda et al. · European Journal of Cancer · 2017
Cited by 42 works. doi:10.1016/j.ejca.2017.08.027 Open-access PDF
Authors
- Jean‐Charles Soria
- Alex A. Adjei
- Rastilav Bahleda
- Benjamin Besse
- Charles Ferté
- David Planchard
- Jing Zhou
- Joseph A. Ware
- Kari M. Morrissey
- Geetha Shankar
- Jennifer L. Schutzman
- Grace Kho Dy
- Harry J.M. Groen
References
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- PI3K and cancer: lessons, challenges and opportunities
- The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Development of PI3K inhibitors: lessons learned from early clinical trials
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
- MYCN and the epigenome
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors